BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33228421)

  • 1. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
    Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
    J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
    Mourton SM; Temple LK; Abu-Rustum NR; Gemignani ML; Sonoda Y; Bochner BH; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Dec; 99(3):608-14. PubMed ID: 16153697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Clark RM; Rice LW; Del Carmen MG
    Gynecol Oncol; 2018 Aug; 150(2):370-377. PubMed ID: 29929923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Readmissions after ovarian cancer cytoreduction surgery: The first 30 days and beyond.
    Mardock AL; Rudasill SE; Lai TS; Sanaiha Y; Wong DH; Sinno AK; Benharash P; Cohen JG
    J Surg Oncol; 2020 Nov; 122(6):1199-1206. PubMed ID: 32700323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
    Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
    Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
    Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
    Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.
    AlHilli M; Langstraat C; Tran C; Martin J; Weaver A; McGree M; Mariani A; Cliby W; Bakkum-Gamez J
    Int J Gynecol Cancer; 2015 Feb; 25(2):193-202. PubMed ID: 25611896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis.
    Fournier M; Huchon C; Ngo C; Bensaid C; Bats AS; Combe P; le FrèreBelda MA; Fournier L; Berger A; Lecuru F
    Eur J Surg Oncol; 2018 Jun; 44(6):750-753. PubMed ID: 29580734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectosigmoid resection morbidity in ovarian cancer cytoreductive surgery.
    Usmani AS; Yasin I; Asif RB; Khalid N; Syed AA
    J Pak Med Assoc; 2023 Jun; 73(6):1284-1287. PubMed ID: 37427631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study.
    Lee TC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Ahmed A; Fournier K; Lee AJ; Dineen S; Powers B; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Zaidi MY; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Abbott DE; Pokrzywa C; Blakely AM; Lee B; Johnston FM; Greer J; Patel SH
    J Gastrointest Surg; 2020 Jan; 24(1):165-176. PubMed ID: 31745888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome.
    Huang D; Harrison R; Curtis E; Mirabadi N; Chen GY; Alexandridis R; Barroilhet L; Rose S; Hartenbach E; Al-Niami A
    Int J Gynecol Cancer; 2023 May; 33(5):741-748. PubMed ID: 36808044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes.
    Erkilinç S; Karataşli V; Demir B; Çakir İ; Can B; Karadeniz T; Gökçü M; Sanci M
    Int J Gynecol Cancer; 2018 Nov; 28(9):1699-1705. PubMed ID: 30371561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Filippova OT; Chi DS; Long Roche K; Sonoda Y; Zivanovic O; Gardner GJ; Tew WP; O'Cearbhaill R; Sarraf S; Sun SW; Alexander K; Korc-Grodzicki B; Shahrokni A
    Gynecol Oncol; 2019 Jul; 154(1):77-82. PubMed ID: 31078241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.
    Peiretti M; Bristow RE; Zapardiel I; Gerardi M; Zanagnolo V; Biffi R; Landoni F; Bocciolone L; Aletti GD; Maggioni A
    Gynecol Oncol; 2012 Aug; 126(2):220-3. PubMed ID: 22555105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectosigmoid resection without colostomy during primary cytoreductive surgery for ovarian carcinoma.
    Sonnendecker EW; Beale PG
    Int Surg; 1989; 74(1):10-2. PubMed ID: 2707991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Bernard L; Boucher J; Helpman L
    Gynecol Oncol; 2020 Sep; 158(3):597-602. PubMed ID: 32641239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.